Plain-English translation of NCT07002034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether RE104, given as a single injection under the skin, can help reduce depression and anxiety in people who are struggling emotionally because of a serious medical illness like cancer, ALS, MS, Parkinson's disease, or pulmonary fibrosis. The medication is being compared to an active placebo (a control injection) to see if it truly makes a difference. Researchers want to understand whether this treatment can help people cope better with the emotional toll of living with these conditions.
When someone is diagnosed with or managing a serious illness like cancer or ALS, it's common to experience depression and anxiety—a condition called adjustment disorder. Current treatments don't work for everyone, and this study is testing whether this new medication could offer another option to help people feel better.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive a single injection under the skin of either a lower dose or higher dose of the medication (or the control injection)—researchers will randomly assign which one you get. You will then be monitored to see how you respond over time, with regular clinic visits to check how you're doing emotionally and physically. The study is small (about 100 participants total), and your emotional health symptoms will be tracked closely to see whether the medication helps reduce your depression and anxiety.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
United States